In current molecular medicine, next-generation sequencing (NGS) for transcript variant detection and multivariable analyses are valid methods for evaluating gene expression, cancer mechanisms, and prognoses of patients. We conducted RNA-sequencing on samples from patients with primary central nervous system lymphoma (PCNSL) using NGS and performed multivariable analysis on gene expression data and correlations focused on Th-1/Th-2 helper T cell balance and immune checkpoint to identify diagnosis/prognosis markers and cancer immune pathways in PCNSL. We selected 84 transcript variants to limit the analysis range for Th-1/Th-2 balance and stimulatory and inhibitory checkpoints in 31 PCNSLs. Of these, 21 highly-expressed transcript variants were composed of the formulas for prognoses based on Th-1/Th-2 status and checkpoint activities. Using formulas, Th-1 low , Th-2 high , and stimulatory checkpoint high resulted in poor prognoses. Further, Th-1 high Th-2 low was associated with good prognoses. On the other hand, CD40-001 high and CD70-001 high as stimulatory genes, and LAG3-001 high , PDCD1 (PD-1)-001/002/003 high , and PDCD1LG2 (PD-L2)-201 low as inhibitory genes were associated with poor prognoses. Interestingly, Th-1 high Th-2 low and Th-1 low Th-2 high were correlated with stimulatory checkpoint low as CD70-001 low and inhibitory checkpoint low as HAVCR2 (TIM-3)-001 low and PDCD1LG2-001/201 low , respectively. Focused on the inhibitory checkpoint, specific variants of CD274 (PD-L1)-001 and PDCD1-002 served severe hazard ratios. In particular, PDCD1-002 high by a cut off score was associated with poor prognoses, in addition to PDCD1-001/003 high , PDCD1LG2-201 low , and LAG3-001 high . These results mainly suggest that expression of transcript variants of PDCD1 and PDCD1LG2 on the Th-1/Th-2 balance enable prognostic prediction in PCNSL. This study provides insights for development of molecular target therapies and identification of diagnosis/prognosis markers in PCNSL. Primary central nervous system (CNS) lymphomas (PCNSLs) are extranodal non-Hodgkin's lymphomas (NHLs) of diffuse large B-cell lymphomas (DLBCLs), localized to the brain, eye, meanings, and spinal cord, which are distinct from systemic lymphomas 1,2 . PCNSLs account for approximately 3% of primary CNS tumors and approximately 1% of NHLs in adults 3 . Most PCNSLs are immune-privileged site-associated DLBCLs, according to the World Health Organization (WHO) diagnostic criteria 1,2 . Despite intensive treatments, including high-dose methotrexate (HD-MTX)-based polychemotherapy and deferred whole brain radiotherapy, the median overall survival (OS) time of PCNSLs was associated with poor prognoses (approximately 4 years) compared to extracerebral DLBCLs 4 .
www.nature.com/scientificreports www.nature.com/scientificreports/ calculated from Cox regression analyses and the fragments per kilobase of exon per million mapped fragments (FPKM) values of genes, to estimate the status of patients with PCNSL like prognoses, as follows:
Th-1 Status = 0.007 × CD4-001 + 0.012 × IFNG-001 + 0.017 × STAT1-001 + 0.012 × STAT1-002 + 0.006 × STAT1-003 + 0.003 × STAT1-010 + 0.001 × STAT1-011 + 0.007 × TNFRSF1A-001 + 0.006 × TNFRSF1A-004 + 0.004 × TNFR SF1B-001 Th-2 Status = 0.018 × CD28-001 + 0.002 × CD28-201 + 0.012 × CD28-202 + 0.011 × CD4-001 + 0.015 × IL18R1-001 + 0.001 × IL18R1-003 + 0.004 × IL18R1-201 + 0.001 × IL18R1-202 + 0.003 × IL2RB-001 + 0.01 × IL10-003 + 0.025 × IL6-001 + 0.002 × IL6-003 + 0.029 × IL6-004 + 0.015 × IL6-005 + 0.005 × IL6-006 + 0.017 × IL6-201 + 0.047 × STAT6-001 + 0.029 × TGFB3-001 Stimulatory checkpoint = 0.003 × IL2RB-001 + 0.013 × TNFRSF18-001 + 0.015 × TNFRSF18-002 + 0.005 × TNFRSF18-003 + 0.003 × CD27-001 + 0.013 × CD40-001 + 0.011 × CD40-002 + 0.015 × TNFRSF4-001 + 0.022 × CD70-001
Inhibitor y checkp oint = 0.004 × AD ORA2A-001 + 0.004 × BTL A-001 + 0.002 × BTL A-002 + 0.007 × PDCD1LG2-001 + 0.01 × PDCD1LG2-201 + 0.025 × CD274-001 + 0.023 × CD274-201 + 0.003 × HAVCR2-001 + 0.009 × IDO1-002 + 0.012 × LAG3-001 + 0.042 × PDCD1-001 + 0.034 × PDCD1-002 + 0.039 × PDCD1-003
Candidates for the prognosis markers in PCNSL. The subgroups by the median scores calculated by each formula divided Kaplan-Meier curves (Fig. 2b) . In particular, the subgroups with Th-1 low (hazard ratio (HR) = 3.8, 95% confidence interval (CI): 1.5-9.9, p = 0.0033) and stimulatory checkpoint high (HR = 3.4, 95%CI: 1.2-10.0, p = 0.014) were associated with poor prognoses with statistical differences (Fig. 2b) . Th-2 high (HR = 2.4, 95%CI: 0.8-6.6, p = 0.072) and inhibitory checkpoint high (HR = 2.1, 95%CI: 0.8-5.6, p = 0.1) also correlated with poor prognoses (Fig. 2b) . As for representative marker candidates of stimulatory checkpoint genes, CD40-001 high (HR = 2.5, 95%CI: 1.0-6.2, p = 0.043) and CD70-001 high (HR = 2.5, 95%CI: 1.0-6.2, p = 0.04) were associated with poor prognoses (Fig. 2c ). On the other hand, as for inhibitory checkpoint genes, LAG3-001 high (HR = 2.8, 95%CI: 1.1-7.1, p = 0.019), PDCD1LG2-201 low (HR = 2.9, 95%CI: 1.2-7.1, p = 0.018), PDCD1-001 high (HR = 3.3, 95%CI: 1.2-9.1, p = 0.012), PDCD1-002 high (HR = 9.3, 95%CI: 2.4-35.7, p = 8.4E-05), and PDCD1-003 high (HR = 2.6, 95%CI: 1.1-6.7, p = 0.032) were associated with poor prognoses (Fig. 2c) with IL2RB-001 high , TNFRSF18-001 high , TNFRSF18-002 high , CD27-001 high , CD40-002 high , TNFRSF4-001 high (Suppl. Fig. S3A ), and TNFRSF18-003 low (Suppl. Fig. S3B ) were associated with poor prognoses, but were not significantly different, as for stimulatory checkpoint genes. Similarly, ADORA2A-001 high , PDCD1LG2-001 high , HAVCR2-001 high (Suppl. Fig. S4A ), BTLA-001/002 low , CD274-001/201 low , and IDO1-002 low (Suppl. Fig. S4B ) were associated with poor prognoses, but were not statistically significant, as for inhibitory checkpoint genes. The specific transcript variants such as CD40-001, CD70-001, LAG3-001, PDCD1LG2-201, and PDCD1-001/002/003 are candidates for immune checkpoint genes for promising prognosis factors to predict OS of PCNSL patients.
Assessment of the balance of Th-1 and Th-2 differentiation in PCNSL.
We next wanted to identify facilitating factors to divide Kaplan-Meier curves and/or to enlarge HR values in the survival analysis in PCNSL. We focused on the balance in Th-1 and Th-2 differentiation. As shown in Fig. 3a , the calculated Th-1 scores were distributed at a wide range, but the calculated Th-2 scores were compacted. The four subgroups with Th-1 high Th-2 high , Th-1 high Th-2 low , Th-1 low Th-2 high , and Th-1 low Th-2 low were generated. Except for Th-1 high Th-2 low , the other three subgroups were associated with poor prognoses in the Kaplan-Meier curves (Fig. 3b,c) . While, Th-1 low Th-2 low was associated with the worst prognosis among the four subgroups (HR = 2.4, 95% CI: 0.6-9.2, p = 0.21) (Fig. 3b,c) . These results suggest that the Th-1 activity and the Th-2 inactivity would contribute to prolonged OS of the PCNSL patients.
Overlay of the transcript variant expression on the Th-1/Th-2 balance in PCNSL. The expression
patterns of transcript variants of genes of interests were examined to investigate the effects on the Th-1/Th-2 balance. In the balance between Th-1/Th-2 differentiation and stimulatory checkpoint genes, lower and higher expression of stimulatory checkpoint genes were overlaid on the Th-1 high Th-2 low and Th-1 low Th-2 high balances, respectively ( Fig. 4a ,c), whereas higher and lower expression of inhibitory checkpoint genes was detected on the Th-1 high Th-2 low and Th-1 low Th-2 high balances, respectively (Fig. 4b,c ), indicating that reciprocal patterns were found in stimulatory and inhibitory checkpoint genes on the Th-1/Th-2 balance. In addition, the changes in Th-1/Th-2 balance were diffused in stimulatory checkpoint genes (p = 0.014) but not in inhibitory checkpoint genes (p = 0.381), in addition to the spread changes in Th-1 (p = 0.003) and Th-2 scores (p < 0.001) ( Fig. 4c ). Additionally, lower and higher expression of CD70-001 on Th-1 high Th-2 low and Th-1 low Th-2 high were found in the stimulatory checkpoint genes, respectively ( Fig. 4d,e ). Similarly, CD27-001 and CD40-001/002 showed similar results with no statistical significances (Suppl . Tables S2, S3 , and Suppl. Fig. S5 ). Inversely, higher and lower expression of PDCD1LG2-001/201, PDCD1-002, and HAVCR2-001 on Th-1 high Th-2 low and Th-1 low Th-2 high were found in the inhibitory checkpoint genes, respectively ( Fig. 4d ,e, and Suppl. Table S2 ). Similarly, BTLA-001/002, CD274-001/201, IDO1-002, LAG3-001, and PDCD1-001/003 showed similar results with no statistical significances (Suppl . Tables S2, S4 , and Suppl. Fig. S6 ). These results suggest that lower expression of stimulatory www.nature.com/scientificreports www.nature.com/scientificreports/ checkpoint genes is correlated with the Th-1 high Th-2 low balance, whereas higher expression of inhibitory checkpoint genes is correlated with the Th-1 low Th-2 high balance. Coupled with the aforementioned results in Figs 2-4, these data clearly suggest that higher expression of inhibitory checkpoint genes on the Th-1 low Th-2 high balance is correlated with a poorer prognosis in PCNSL. www.nature.com/scientificreports www.nature.com/scientificreports/
Inhibitory checkpoint genes are satisfied with central factors for prognosis prediction in PCNSL.
Considering the aforementioned results, we next focused on the inhibitory checkpoint genes. After random survival forests analysis and PCA, we found that each variable importance of PDCD1-001/002/003, KIR3DL1-002, PDCD1LG2-201, LAG3-001, and CD274-001 especially contributed to OS of PCNSL patients (Fig. 5a ). Cox regression analysis also revealed that higher expression of PDCD1-002 (HR = 15.83, 95%CI: 3.17-79.09, p = 0.001), CD160-006 (HR = 5.79, 95%CI: 1.68-20.02, p = 0.006), CD160-007 (HR = 72.39, 95%CI: 2.89-1811.75, p = 0.009), CEACAM1-202 (HR = 3.57, 95%CI: 1.85-6.89, p < 0.001), LGALS9-005 (HR = 43.97, 95%CI: 6.21-311.43, p < 0.001), in addition to CD274-001 (HR = 0.94, 95%CI: 0.85-1.03, p = 0.176), was correlated with higher hazard ratios for OS ( Fig. 5b) .
The Kaplan-Meier survival analysis also showed that the identical cut off values on each expression of PDCD1-001 (cut off = 6.87), PDCD1-002 (cut off = 0.37), PDCD1-003 (cut off = 0.29), PDCD1LG2-201 (cut off = 0.42), and LAG3-001 (cut off = 5.01) reconstituted from the Kaplan-Meier results by their median expression (Figs 2c and 5c), in addition to higher expression of CD80-001 (cut off = 12.72), CEACAM1-011 (cut off = 0.3), CEACAM1-202 (cut off = 0.87), LGALS9-001 (cut off = 0.09), LGALS9-002 (cut off = 0.26), and LGALS9-005 (cut off = 0.48) with poor prognoses (Fig. 5c ). On the other hand, higher expression of CD160-006/007/202, CD276-002/201, CD86-002, CD96-001, CEACAM1-003/004/005, CTLA4-001/005, HAVCR2-201, LGALS3-001, PDCD1LG2-001, PVR-002/003/006, TIGIT-201, TMIGD2-001, TNFRSF14-001/009, KIR3DL1-201, and VTCN1-201 by each cut off value correlated with poorer prognoses with no statistical significance in PCNSL (Suppl. Fig. S7 ). Inversely, lower expression of LGALS9-002 (cut off = 1.06) was associated with poorer prognoses (Fig. 5c ). In addition, lower expression of BTLA-001/002, C10orf54-001, CD160-201, CD274-001/201, CD80-202, CD86-001/201, CD96-002, CEACAM1-001/002, IDO1-002, LGALS9-201, PVR-004, KIR3DL1-003, and VTCN1-001/002 by each cut off value was associated with poor prognoses with no statistically significant in PCNSL (Suppl. Fig. S8 ). These results suggest that the specific transcript variants derived from inhibitory checkpoint genes, especially PDCD1-001/002/003, PDCD1LG2-201, and LAG3-001, would be satisfied with central factor candidates for prognosis prediction in PCNSL. In other word, these transcript variants may be promising prognosis marker candidates in PCNSL.
Correlation analysis among Th-1/Th-2 differentiation and immune checkpoint genes in PCNSL.
To validate the correlation between expression of checkpoint genes and the Th-1 and Th-2 status, additional analysis for the correlation among Th-1/Th-2 differentiation and expression of stimulatory and inhibitory immune checkpoint genes was carried out. The analysis for the correlations between multiple pairs of variables returned representative Pearson's rank correlation coefficient values (r) with statistical significances by additional nonparametric analyses, which were summarized in the matrix (Suppl. Fig. S9A ). The variable 1, including HAVCR2-001, LAG3-001, PDCD1LG2-001, ICOS-001, IDO1-002, and CTLA4-001, is correlated with the variable 2, including CD28-001, STAT4-002, IFNG-001, CD4-001, CD28-202, and TBX21-001, with relative high correlation coefficient values (r > 0.47, p < 0.05) (Suppl. Fig. S9A ). The results suggested that a complex correlation www.nature.com/scientificreports www.nature.com/scientificreports/ network was constituted of the variable 1, mainly composed of inhibitory checkpoint genes, and the variable 2, principally composed of developmental status of Th-1 differentiation (Suppl. Fig. S9A ). Nonparametric analyses with Spearman, Kendall rank distance, and Hoeffding independence test also indicated that the variable www.nature.com/scientificreports www.nature.com/scientificreports/ 1, including BTLA-002, CD274-001, HAVCR2-001, ICOS-001, LAG3-001, PDCD1LG2-001/201, STAT4-002, TNFRSF18-001, and TNFRSF1A-001, was correlated with the variable 2, including BTLA-001, PDCD1LG2-001, TNFRSF1A-001, CD28-001, TBX21-001, CD4-001, STAT1-001, and IFNG-001, with relative high correlations (r > 0.3, p < 0.05) (Suppl. Fig. S9B ). Besides, in part of the genes analyzed, the schematic representation of their correlation with graphical lasso showed that HAVCR2-001 and PDCD1LG2-001, both inhibitory checkpoint genes, were pivotal factors with important nodes in the Th-1/Th-2 network, followed by TNFRSF1A-001, IFNG-001, STAT1-001, and CD4-001 ( Fig. 6a ). CD28-202-to-LAG3-003 interaction connected the Th-1/Th-2 gene network and the immune checkpoint gene network, suggestive of an important network hub between the two (Fig. 6a ). Further, focused on the inhibitory checkpoint network and extracted them, PDCD1LG2-201, CD274-001, and VTCN1-001/002 seemed a network hub into the complex inhibitory checkpoint gene network (Fig. 6b ). These correlation analysis results suggest that expression control of the hub genes with several nodes, including HAVCR2-001, PDCD1LG2-001/201, CD274-001, and VTCN1-001/002, can reconstitute the complex network composed of Th-1/Th-2 status and immune checkpoint genes and their balances.
Pathway analysis on the cancer immunotherapy-related genes in PCNSL.
We finally performed gene set enrichment analysis (GSEA) using the dataset. In this study, 7565 known genes were detected after sequencing, and the 337 genes of these found in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. While, the genes with differential expression in the PCNSL subgroup with poor prognoses (cutoff by median OS), compared that with good prognoses, were 3140, and the 59 genes found in the KEGG. Of these, the average expression of the two genes, including CD70 and PDCD1, and the 12 isoforms derived from the seven genes, including CD40, CD70, IL6, IL10, STAT1, STAT6, and TNFRSF14, were cancer immunotherapy-related genes (false discovery rate (FDR) < 0.01) ( Table 2 ). In the GSEA with KEGG, 10 pathways on "expression analysis of the gene" and 16 pathways on "expression analysis of the transcript variant" analysis included 31 genes and 139 transcript variants, respectively (p < 0.05; Table 3 , and FDR < 0.01; Suppl. Table S5 ). In particular, T cell receptor signaling pathway (KEGG ID: hsa04660) (Suppl. Fig. S10 ), cytokine-cytokine receptor interaction (hsa04060) (Suppl. Fig. S11 ), and cell adhesion molecules (hsa04514) (Suppl. Fig. S12 ) may be involved in cancer immunotherapy. While, since the complete data of all genes or transcripts is more unbiased in the PCNSL clinical samples, systematic approaches may return different results.
Discussion
Here, we performed NGS for distinct transcript variant detection and multivariable analyses for evaluating prognoses in 31 patients suffering PCNSL and for discovering a stimulus-dependent oncopathway input from tumor microenvironments, including activated T cells, and stimulatory and inhibitory immune checkpoints in PCNSL. In particular, we focused on the correlation between checkpoint genes and Th-1/Th-2 differentiation to estimate OS of PCNSL patients. Data showed lower and higher expression of Th-1 and Th-2 differentiation genes with poorer prognoses, respectively. CD40-001 high and CD70-001 high as stimulatory checkpoint genes and LAG3-001 high , PDCD1 (PD-1)-001/002/003 high , and PDCD1LG2 (PD-L2)-201 low as inhibitory checkpoint genes also were associated with poorer prognoses. Th-1 high Th-2 low and Th-1 low Th-2 high were correlated with lower expression of CD70-001, and PDCD1LG2-001/201 and HAVCR2 (TIM-3)-001 for inhibitory checkpoint. For inhibitory checkpoint genes, Cox regression analysis showed higher HR in the expression of CD274 (PD-L1)-001, CD160-006/007, LGALS9-005, CEACAM1-202, and PDCD1-002. Further, higher expression of inhibitory checkpoint genes, including PDCD1-001/002/003, PDCD1LG2-201, and LAG3-001, with a cut off score reconstituted successfully the Kaplan-Meier curves estimated by the median expression. Besides, correlation coefficient analyses indicated that inhibitory checkpoint genes, including HAVCR2-001 and PDCD1LG2-001, governed the Th-1/ Th-2 differentiation network. In addition, CD28-202 genetically interacted with LAG3-001, a hub gene of the checkpoint gene network bridging to the Th-1/Th-2 network in PCNSL. The GSEA with KEGG also clarified gene networks harboring differential expression of the PDCD1 gene, T-cell receptor signaling, cytokine interaction, and cell adhesion. These results suggest that identical expression of transcript variants of inhibitory immune checkpoint genes overlaid on the Th-1/Th-2 balance enables to predict survival distributions in PCNSL patients.
On the other hand, we also examined the dataset of DLBCL (n = 47) deposited in The Cancer Genome Atlas (TCGA) for the Th-1/Th-2 status and the immune checkpoint molecule scores (Suppl. Figs S13 and S14). The results from the DLBCL were as follows: (i) Th-1 score was correlated with Th-2 score (Suppl. Fig. S13E ). (ii) Th-1 low was correlated with lower expression of inhibitory checkpoint gene expression (Suppl. Fig. S13I ). (iii) The LGALS9 low showed poor prognoses (Suppl. Fig. S14F ). (iv) Differential expression of PDCD1 or PDCD1LG2 did not divide survival curves in DLBCL (Suppl. Fig. S14H and I) . Hence, we considered that the correlation between Th-1/Th-2 balance and checkpoint gene expression is significant in PCNSL but not in DLBCL. Thus, this study may provide insights for development of molecular target therapies and identification of diagnosis and prognosis markers based on NGS and multivariable analysis in PCNSL.
As described above, we only examined the Th-1/Th-2 balance and checkpoint genes, including PD-1, the ligands, and the other antigen molecules. However, the differentiation status of other T cells such as regulatory T cells (Treg) [23] [24] [25] [26] [27] [28] , Th-17 cells 27 , CD4 + 27 , CD8 + cells 16 , and macrophages within tumor microenvironments 15 contribute to immune checkpoint activity via intrinsic and extrinsic factors in tumor cells or T cells 14, [29] [30] [31] . On the other hand, MTX is an antifolate that inhibits DNA syntheses 32 and the expression of glucocorticoid receptors in human blood cells 33 . HD-MTX treatment and deferred radiotherapy are a standard protocol for PCNSL treatment; nevertheless, most of the cases come to relapse-acquired resistances 4 . Recent studies showed that immune checkpoint blockade with monoclonal antibodies against the cell surface antigens, including CTLA-4, ipilimumab, and PD-1, nivolumab and/or pembrolizumab 34 , and a combination anti-PD-1/CTLA-4 regimens (nivolumab-ipilimumab) have been effective against melanoma 35 , lung cancer 31 , gastrointestinal tract cancer 36 , urologic cancer 37 , and liver cancer 38 . However, it has also been reported that tumor and T-cell intrinsic and extrinsic factors contribute to immunotherapy resistances such as adaptive immune and acquired resistances, except for patients who have primary resistance to checkpoint inhibitors 30 . Hence, it is important to prevent the recurrences with chemical and checkpoint inhibition resistance in PCNSL treatments 39, 40 .
In addition to CTLA-4 and PD-1, recent trends shifted to alternative inhibitory receptors and their mechanisms within tumor microenvironments. LAG-3 is considered the third inhibitory receptor candidate in clinics in the next generation 41 , whereasTIM-3 is expressed in FoxP3 + Treg and activates Treg function, and the TIM-3 blockade has therapeutic effects in a preclinical model 42 . TIM-3 also functions on the IFN-γ-producing T-cells, macrophages, and dendritic cells, where it leads to the inhibition of Th-1 responses 42 . Therefore, multi-targeting of LAG-3, TIM-3, PD-1, and/or CTLA-4 may serve as a next generation cancer immunotherapy. However, these molecules are also responsible for a primary or adaptive resistance for immunotherapy 30 . PDCD1LG2 also Table 2 . Differential expression of genes in the poor prognosis subgroup, compared to the good prognosis subgroup. Note: a FC; fold change, b CPM; counts per million, c LR; likelihood ratio, and d FDR; false discovery rate. Subgroups were divided by the median overall survival of PCNSL patients analyzed.
